Behavioral and Neurochemical Effects of 5-{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843): A Combined Selective Inhibitor of Serotonin Reuptake and 5-Hydroxytryptamine1A Receptor Partial Agonist

@article{Page2002BehavioralAN,
  title={Behavioral and Neurochemical Effects of 5-\{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl\}-benzofuran-2-carboxamide (EMD 68843): A Combined Selective Inhibitor of Serotonin Reuptake and 5-Hydroxytryptamine1A Receptor Partial Agonist},
  author={Michelle E. Page and John F. Cryan and A. O. Sullivan and Ashutosh Dalvi and Berangere Saucy and David R Manning and Irwin Lucki},
  journal={Journal of Pharmacology and Experimental Therapeutics},
  year={2002},
  volume={302},
  pages={1220 - 1227}
}
  • M. Page, J. Cryan, I. Lucki
  • Published 1 September 2002
  • Biology
  • Journal of Pharmacology and Experimental Therapeutics
5-{4-[4-(5-Cyano-3-indolyl)-butyl)-butyl]-1-piperazinyl}-benzofuran-2-carboxamide (EMD 68843; vilazodone) is a novel compound with combined high affinity and selectivity for the 5-hydroxytryptamine (5-HT) transporter and 5-HT1A receptors. EMD 68843 was tested as a prototype compound, which benefits from dual pharmacological effects that could increase extracellular 5-HT to levels higher than those produced by conventional selective serotonin reuptake inhibitors (SSRIs). In Sf9 cells, EMD 68843… 
View on ASPET
jpet.aspetjournals.org
87 Citations
Highly Influential Citations
6
Background Citations
28
Methods Citations
6
Results Citations
4

Figures and Tables from this paper

87 Citations

Dual 5-HT1A agonists and 5-HT re-uptake inhibitors by combination of indole-butyl-amine and chromenonyl-piperazine structural elements in a single molecular entity.
Neurochemical evaluation of the novel 5-HT1A receptor partial agonist/serotonin reuptake inhibitor, vilazodone.
Studies toward the discovery of the next generation of antidepressants. Part 6: Dual 5-HT1A receptor and serotonin transporter affinity within a class of arylpiperazinyl-cyclohexyl indole derivatives.
Novel 4-aryl-pyrido[1,2-c]pyrimidines with dual SSRI and 5-HT(1A) activity. Part 5.
Electrophysiological evidence for rapid 5-HT₁A autoreceptor inhibition by vilazodone, a 5-HT₁A receptor partial agonist and 5-HT reuptake inhibitor.
Synthesis and biological evaluation of novel pyrrolidine-2,5-dione derivatives as potential antidepressant agents. Part 1.
Mechanism of action of the bimodal antidepressant vilazodone: evidence for serotonin1A-receptor-mediated auto-augmentation of extracellular serotonin output
TLDR
In spite of high intrinsic 5-HT1A activity in reserpinized rats, the net effect of vilazodone at release-regulating 5- HT1A autoreceptors must be inhibitory, leading to markedly increased 5-ht output.
Effect of vilazodone on 5-HT efflux and re-uptake in the guinea-pig dorsal raphe nucleus.
Involvement of kynurenine pathway and N-methyl-d-aspartate receptors in the antidepressant-like effect of vilazodone in the tail suspension test in mice
Chapter 6 Association of 5-HT 1 A Receptors with Affective Disorders
TLDR
The purpose of this chapter is to analyze and discuss the current information about 5-HT 1A -R-mediated signaling cascades, the intracellular signaling of 5- HT 1A-R, in addition to their expression and pharmacology that are important to treatment of affective disorders symptoms.
...
...

References

SHOWING 1-10 OF 68 REFERENCES
EMD 68843, a serotonin reuptake inhibitor with selective presynaptic 5-HT1A receptor agonistic properties.
WAY100135: a novel, selective antagonist at presynaptic and postsynaptic 5-HT1A receptors.
Antidepressant-like behavioral effects in 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) receptor mutant mice.
TLDR
The results suggest that 5-HT(1A) and 5- HT(1B) receptors have different roles in the modulation of the response to antidepressant drugs in the TST, suggesting mediation by enhanced catecholamine function.
Agonist-independent activation of Gz by the 5-hydroxytryptamine1A receptor co-expressed in Spodoptera frugiperda cells. Distinguishing inverse agonists from neutral antagonists.
TLDR
The human 5-hydroxytryptamine1A receptor, when expressed in Spodoptera frugiperda (Sf9) cells, facilitates the binding of [35S]GTPgammaS to a co-expressed GTP-binding regulatory protein, Gz, consistent with constitutive activity, using G protein activation as an index of receptor activity.
Idazoxan and 8-OH-DPAT Modify the Behavioral Effects Induced by Either NA, or 5-HT, or Dual NA/5-HT Reuptake Inhibition in the Rat Forced Swimming Test
Postsynaptic 5-HT1A receptors mediate 5-hydroxytryptamine release in the amygdala through a feedback to the caudal linear raphe.
Genetic regulation of extracellular serotonin by 5-hydroxytryptamine(1A) and 5-hydroxytryptamine(1B) autoreceptors in different brain regions of the mouse.
TLDR
Results indicate common topographical regulation of 5-HT release in different brain regions by genetic mutation and pharmacological challenges and play a larger role in regulating 5- HT release in the striatum and possibly other brain regions innervated by the dorsal raphe nucleus.
Partial 5-HT1A receptor agonist properties of (–)pindolol in combination with citalopram on serotonergic dorsal raphe cell firing in vivo
TLDR
The present findings support the previous notion that (–)pindolol possesses prominent agonistic activity at somatodendritic 5-HT1A autoreceptors, but also indicate that it may possess a weak antagonistic action at these receptors.
Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis.
Effects of (−)‐tertatolol, (−)‐penbutolol and (±)‐pindolol in combination with paroxetine on presynaptic 5‐HT function: an in vivo microdialysis and electrophysiological study
TLDR
The data suggest that (-)‐tertatolol and (−)‐penbutolol are superior to (±)‐pindolol in terms of enhancing the effect of an SSRI on extracellular 5‐HT in the frontal cortex and both are worthy of investigation for use as adjuncts to SSRIs in the treatment of major depression.
...
...